Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker IPHA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors NCT06781983 · Advanced or Metastatic Solid Tumors IPH4502 | IPHA Innate Pharma | Phase 1 | Active, not recruiting | 145 | Apr 2028 | Registry ↗ |
| Jun 17, 2026 | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) NCT05742607 · Non Small Cell Lung Cancer IPH5201 + durvalumab + standard chemotherapy | IPHA Innate Pharma | Phase 2 | Recruiting | 70 | Jun 2027 | Registry ↗ |
| May 14, 2026 | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Mu… NCT01222286 · Smoldering Multiple Myeloma IPH2101 | IPHA Innate Pharma | Phase 2 | Completed | 30 | Jul 2012 | Registry ↗ |
| Apr 29, 2026 | IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lympho… NCT03902184 · Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous IPH4102 | IPHA Innate Pharma | Phase 2 | Completed | 170 | Jan 8, 2026 | Registry ↗ |
| Apr 14, 2026 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma NCT06088654 · Non Hodgkin Lymphoma IPH6501 | IPHA Innate Pharma | Phase 1/2 | Terminated | 23 | Feb 6, 2026 | Registry ↗ |
| Mar 28, 2024 | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma Th… NCT05321147 · Peripheral T Cell Lymphoma lacutamab | IPHA Innate Pharma | Phase 1 | Completed | 20 | Nov 19, 2023 | Registry ↗ |
| May 12, 2023 | Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma… NCT02643550 · Head and Neck Neoplasms Monalizumab, Cetuximab | IPHA Innate Pharma | Phase 1/2 | Completed | 143 | Mar 28, 2023 | Registry ↗ |
| Jan 27, 2022 | IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors NCT03665129 · Advanced Solid Tumors IPH5401 and Durvalumab | IPHA Innate Pharma | Phase 1 | Terminated | 73 | Feb 24, 2021 | Registry ↗ |
| Jan 20, 2021 | Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) NCT02593045 · Cutaneous T-Cell Lymphoma IPH4102 | IPHA Innate Pharma | Phase 1 | Completed | 44 | Apr 2020 | Registry ↗ |
| Dec 17, 2019 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Unt… NCT02557516 · Chronic Lymphocytic Leukemia monalizumab | IPHA Innate Pharma | Phase 1/2 | Terminated | 22 | Oct 29, 2018 | Registry ↗ |
| Feb 8, 2019 | Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (… NCT01687387 · Acute Myeloid Leukemia IPH2102 at 0.1 mg/kg, IPH2102 at 1 mg/kg | IPHA Innate Pharma | Phase 2 | Completed | 152 | Nov 17, 2016 | Registry ↗ |
| Jan 4, 2017 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity NCT02331875 · Squamous Cell Carcinoma of the Oral Cavity IPH2201, Standard Surgery | IPHA Innate Pharma | Phase 1/2 | Terminated | 3 | Dec 2016 | Registry ↗ |
| Mar 31, 2016 | An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects… NCT00552396 · Multiple Myeloma Anti-KIR (1-7F9) | IPHA Innate Pharma | Phase 1 | Completed | 32 | Jan 2011 | Registry ↗ |
| Mar 24, 2016 | Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients… NCT00999830 · Multiple Myeloma IPH2101 | IPHA Innate Pharma | Phase 2 | Completed | 27 | Jun 2012 | Registry ↗ |
14 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:40 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances